Loading...
Keywords
Last Name
Institution

Search Results (26)

Click the Why column to see why an item matched the search.

MatchTypeWhy
PharmVar GeneFocus: CYP2C9.Academic Article Why?
Cytochrome P-450 CYP2C9Concept Why?
Cytochrome P-450 CYP2C9 InducersConcept Why?
Cytochrome P-450 CYP2C9 InhibitorsConcept Why?
Gaedigk, AndreaPerson Why?
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.Academic Article Why?
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.Academic Article Why?
CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements.Academic Article Why?
Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations.Academic Article Why?
Efficiency of CYP2C9 genetic test representation for automated pharmacogenetic decision support.Academic Article Why?
Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.Academic Article Why?
Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin.Academic Article Why?
VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.Academic Article Why?
Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX: A GeT-RM Collaborative Project.Academic Article Why?
Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.Academic Article Why?
Per Page    Page  of 2last Nextnext
Prev
Search Criteria
  • CYP2C9
Filter by Type